



# Maple-Brown Abbott Australian Share Fund Wholesale

## Monthly Commentary – 30 November 2024

### Fund performance (%)<sup>1</sup>

	1 month	3 months	1 year	3 years p.a.	4 years p.a.	5 years p.a.	Since inception p.a. 31 May 1998
Fund <sup>2</sup>	3.0	3.3	20.4	11.2	12.5	7.9	8.3
Benchmark <sup>3</sup>	3.8	5.5	23.4	9.6	11.0	8.3	8.8

### Market commentary

The Australian equity market had a strong month, with the S&P/ASX 200 Total Return Index rising 3.8%, broadly consistent with global equity markets. Bond yields fell, with the US 10-year government yield down 0.11% to 4.17% and the Australian 10-year down 0.16% to 4.34%. Commodity markets were mixed, including stable prices for iron ore and modest decline for oil. Looking at performance by sector, Information Technology (+10%) performed best, followed by Utilities (+9%) and Financials (+7%). Materials (-3%) was weakest, followed by Energy (-1%) and Consumer Staples (+1%).

### Portfolio commentary

The Fund returned 3.0% over the month, underperforming the benchmark by 0.8%.

Our overweight holding in Origin Energy (+13%) was a key positive contributor to performance. Wholesale electricity futures strengthened over the month which, combined with softening thermal coal prices, should support the earnings outlook for Origin's Energy Markets division. Origin also announced the expansion of its Eraring battery project, extending its duration to 4 hours, as it continues to build its portfolio of renewable generation and storage in anticipation of the closure of the Eraring coal-fired power station.

Our holdings in general insurers Insurance Australia Group (+14%) and QBE Insurance Group (+16%) outperformed. The sector rallied

hard early in the month due to Trump's US election victory, with his policies considered inflationary and thereby leading to higher-for-longer interest rates, which benefits the insurers. This sentiment endured, despite a sharp moderation in bond yields later in the month. In the case of IAG, the announcement of its acquisition of a majority stake in RACQ's insurance business and a 25-year exclusive agreement to provide RACQ insurance products was well received. The transaction materially increases IAG's exposure to Queensland and should be Earnings Per Share accretive. QBE also issued a Q3 trading update during the month, at which it reaffirmed full-year guidance.

Our underweight exposure to the banking sector detracted from performance. In particular, our decision not to hold Commonwealth Bank of Australia (+11%) was the largest single detractor for the month. Our overweight position in Endeavour Group (-7%) was one of a number of defensive names that contributed negatively. The company gave a first quarter trading update during the month, which disappointed the market. Sales momentum in its retail business remains weak, impacted by market-wide factors including cyclical consumer pressures. Management also gave retail EBIT margin guidance below market expectations, impacted by volume deleverage as well as changing consumer behaviours such as trading down and increased buying on promotion. Our overweight position in Santos (-2%) also detracted. The key driver was a softer oil price, reflecting easing geopolitical concerns and the prospect that the US may look to materially increase oil production.

### Please see next page for Outlook

#### Notes:

- 1 Past performance is not a reliable indicator of future performance. Source: Maple-Brown Abbott Ltd, S&P as at 30 November 2024.
- 2 The Fund's performance relates to wholesale investors only. If you are a retail investor, you can obtain up to date returns at [maple-brownabbott.com.au](http://maple-brownabbott.com.au). Total return is based on the movement in withdrawal price per unit plus distributions and is before tax and after all fees and charges. Imputation credits.
- 3 The benchmark is S&P/ASX 200 Total Return Index.

### Want to find out more?

Contact our Client Service team by:

T 1300 097 995

E [mba@unitregistry.com.au](mailto:mba@unitregistry.com.au)

W [maple-brownabbott.com](http://maple-brownabbott.com)

Signatory of:



# Maple-Brown Abbott Australian Share Fund Wholesale

Monthly Commentary – 30 November 2024

## Outlook

Global equity markets remain near record levels, supported by the start of the interest rate cutting cycle in the US, UK and Europe. Within the Australian market, we have seen a rotation into cyclicals, notably the banks. This reflects a growing consensus view that we will achieve a 'goldilocks' scenario whereby we see continued solid corporate earnings and inflation falls to acceptable levels, allowing interest rates to be reduced. The narrative of falling rates has also supported many growth stocks, particularly in the technology sector. This rotation has come at the expense of defensive sectors such as consumer staples and communication services. Resources have also lagged.

Looking ahead, we are of the view that markets are not fully pricing in the economic and geopolitical risks that exist. In Australia, growth remains very weak but, with inflation still elevated, rate cuts are unlikely in the near term. In the US, economic growth appears stronger and bond markets suggest the trajectory of rate cuts will be slower than previously expected. Within equity markets, the rotation noted earlier has presented opportunities, with many defensives now offering attractive valuations and some protection against equity market uncertainties. We continue to see appeal in the energy sector and selected resources, given discounted valuations and strong balance sheets. That said, we observe that many cyclical, technology and other premium-rated industrial stocks appear expensive, and our portfolio remains well underweight those segments.

For latest Fund factsheet [click here](#).

## Disclaimer

This document is prepared and issued by Maple-Brown Abbott Limited ABN 73 001 208 564, AFSL 237296 ("MBA"). This document contains general information only, and does not take into account your investment objectives, financial situation or specific needs. Before making any investment decision, you should seek independent investment, legal, tax, accounting or other professional advice as appropriate. Past performance is not a reliable indicator of future performance. Neither MBA, nor any of its related parties, directors or employees, make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the taxation consequences of, any investment. Any views expressed on individual stocks or other investments, or any forecasts or estimates, are not a recommendation to buy, sell or hold, they are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this document. The views and opinions contained in this document are those of the authors as at the date of publication and are subject to change due to market and other conditions. Such views and opinions may not necessarily represent those expressed or reflected in other MBA communications, strategies or funds. Information derived from sources is believed to be accurate, however such information has not been independently verified and may be subject to assumptions and qualifications compiled by the relevant source and this document does not purport to provide a complete description of all or any such assumptions and qualifications. To the extent permitted by law, neither MBA, nor any of its related parties, directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of this information, or accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on this information. Before making a decision whether to acquire, or to continue to hold an investment in the Fund, you should obtain and consider the current Product Disclosure Statement, Additional Information Booklet and Target Market Determination which is available at [maple-brownabbott.com/document-library](http://maple-brownabbott.com/document-library) or by calling 1300 097 995. This information is current as at 30 November 2024 and is subject to change at any time without notice.

© 2024 Maple-Brown Abbott Limited

## Want to find out more?

Contact our Client Service team by:

T 1300 097 995

E [mba@unitregistry.com.au](mailto:mba@unitregistry.com.au)

W [maple-brownabbott.com](http://maple-brownabbott.com)

Signatory of:

